Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Keybanc analyst Aleksey Yefremov initiated coverage on Avient Corporation (NYSE:AVNT) with an Overweight rating and announced a price target of $48. Avient shares closed at $35.77 on Tuesday. See how other analysts view this stock.
- Barclays analyst Etzer Darout initiated coverage on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) with an Overweight rating and announced a price target of $72. Protagonist Therapeutics shares closed at $58.59 on Tuesday. See how other analysts view this stock.
- Citigroup analyst Samantha Semenkow initiated coverage on Biohaven Ltd. (NYSE:BHVN) with a Buy rating and announced a price target of $28. Biohaven shares closed at $13.49 on Tuesday. See how other analysts view this stock.
- Barclays analyst Etzer Darout initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with an Underweight rating and announced a price target of $13. Summit Therapeutics shares closed at $18.12 on Tuesday. See how other analysts view this stock.
- Bernstein analyst Zhihan Ma initiated coverage on Five Below, Inc. (NASDAQ:FIVE) with a Market Perform rating and announced a price target of $160. Five Below shares closed at $149.06 on Tuesday. See how other analysts view this stock.
Considering buying PTGX stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
